Turning to Goblet Althought we are in the last week of waiting about the Bracelet updated data on Saturday and then the kol talk on Monday, I am also wondering about the other Goblet arms.
We are scheduled (based on the ONCY presentation to have updated results on first line panc in second half of 2023, while they are also waiting to give us some initial results for first and third line colorectal cancer, and anal cancer.
Do we know when these data will be released? Is there a conference at which they are planning to release this data? If so, when is that conference? What about abstracts etc? Have they been submitted?
Anyone with some information to pass on to all of us?
Roche now seems to be a very likely candidate for partnership/buyout. They have tecentriq which seems to work well with pela based on the initial panc results. Tecentriq is licensed for a vast array of cancers and accounts for about 12% of Roche's pharma revenues, IIRC.